| name | es-gh-treatment-oncologist-consult |
| description | This skill determines when to discuss growth hormone treatment appropriateness and timing with the oncologist for childhood cancer survivors who have chronic stable disease (not definitively disease-free) following malignant disease treatment. Triggers include: "Should I involve oncology in GH decision for this survivor with stable disease?" or "Is oncologist input needed for GH timing in persistent disease?" |
Assess need for oncologist consultation for GH therapy
STEP 1 — Gather Information
Collect cancer diagnosis, treatment details (especially radiation dose to hypothalamic–pituitary axis and optic pathway involvement), current disease status (stable vs disease-free) from recent imaging and oncology follow‑up, confirm GH deficiency if tested, and assess growth parameters.
Action: Determine if the survivor has chronic stable disease (not definitively disease‑free) after malignant disease treatment.
STEP 2 — Rule In / Rule Out
Is the disease chronic stable (not definitively disease‑free)?
- Yes: Proceed to discuss GH appropriateness and timing with oncologist.
- No (disease‑free >1 year): Oncologist consultation per guideline is not required for GH timing; follow standard practice of initiating GH after 1 year disease‑free.
Decision: If disease‑free >1 year, defer to standard GH initiation without oncologist input; otherwise proceed to oncologist discussion.
STEP 3 — Classify or Stratify
Among those with chronic stable disease, stratify by tumor type: optic pathway glioma or other CNS tumors indicate higher urgency for oncologist input; other solid tumors still require discussion but may be less urgent.
Action: Classify urgency of oncologist consultation based on tumor histology and radiation dose to the hypothalamic–pituitary axis.
STEP 4 — Decide
Initiate a discussion with the oncologist regarding the appropriateness of GH therapy and the optimal timing, document the shared decision‑making, and defer GH initiation until oncologist input is obtained.
Action: Proceed with GH therapy only after oncologist consensus or clear recommendation.
Clinical Guardrails / Mimics / Pitfalls
Do not start GH therapy without oncologist input in survivors with chronic stable disease; do not rely solely on disease‑free status without confirming via imaging and oncology follow‑up; do not overlook optic pathway glioma history as a high‑risk scenario requiring early oncologist involvement; avoid delaying discussion until after GH has been started.
Concrete Clinical Example
A 12‑year‑old with history of optic pathway glioma treated with 18 Gy hypothalamic–pituitary radiation, currently stable on surveillance MRI (not disease‑free), confirmed GH deficiency, and progressive short stature. The clinician gathers treatment and disease info, determines chronic stable disease, rules in need for oncologist consult, classifies as optic pathway glioma (high priority), decides to discuss GH therapy timing with the oncologist before considering GH initiation.
Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, DOI:10.1210/jc.2018-01175
